Trial ID or NCT#

NCT00822926

Status

NOT RECRUITING

Purpose

Superficial injection of Botulinum toxin has been advocated for cosmetic purposes but has also been reported to be helpful for some pain conditions. The investigators have observed prolonged profound analgesia following subcutaneous superficial injection of Botulinum Toxin Type A (BTA) in patients with certain types of neuropathic pain. the investigators propose to study if addition of BTA extends pain relief compared to placebo when injected subcutaneously into areas of cutaneous allodynia (the property that a normally non-noxious stimulus is perceived as painful).

Official Title

Subcutaneous Botulinum Toxin for Cutaneous Allodynia - Enriched Responder Trial

Eligibility Criteria

Ages Eligible for Study: 18 Years to 100 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Sean Mackey, MD, PhD
Pain management specialist, Anesthesiologist
Redlich Professor and Professor, by courtesy, of Neurology at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Charlie Wang
(650) 723-8250